Azure Health Technology completes study protocol for Pancreatic Cancer Phase II clinical study
Glenn Tong
Chief Executive Officer and Managing Director at VGI Health Technology Limited (NSX:VTL)
Sydney, Australia 21 September 2020 – Azure Health Technology Limited (AZT) today announced that it has completed the preparation of a study protocol for a Phase II clinical study on Pancreatic Adenocarcinoma (Pancreatic Cancer) and has received supportive feedback from Key Opinion Leaders (KOLs). See link for press release with details and what cancer expert Professor Richard Pestell AO has to say about this clinical study.
Congratulations, this always an exciting time.
Chief Executive Officer and Managing Director at VGI Health Technology Limited (NSX:VTL)
4 年Thank you Anthony....the Azure Health team is very excited about moving this important program forward and getting great support from Key Opinion Leaders in cancer research
Corporate Advisor at Novus Capital Limited
4 年Well done Azure Health Technology!